TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06897527: Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recur

Sponsor: GlaxoSmithKline · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,827,200

Rescue Site Savings

+$7,798,560

Unlock Full NCT06897527 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06897527 Rescue Dossier →